Rchr
J-GLOBAL ID:201801001580930888
Update date: Sep. 04, 2024
HIKITA TOMOYA
ヒキタ トモヤ | HIKITA TOMOYA
Affiliation and department:
University of Shizuoka School of Pharmaceutical Sciences
About University of Shizuoka School of Pharmaceutical Sciences
Search "University of Shizuoka School of Pharmaceutical Sciences"
Detailed information
Homepage URL (1):
https://w3pharm.u-shizuoka-ken.ac.jp/radiobio/index.html
Research field (3):
Pharmaceuticals - health and biochemistry
, Cell biology
, Tumor biology
Research theme for competitive and other funds (11):
2024 - 2026 好中球のMDEVsを利用したDDSの開発と脳梗塞治療への応用
2024 - 2025 細胞外小胞による臓器間ネットワークの解明とその生理学的意義
2022 - 2025 生体イメージングに基づいたがん細胞外小胞による脂肪分解機構の解析
2022 - 2024 持続的な培地回収システムを用いた高機能エクソソームの探索と薬物送達への応用
2022 - 2023 生体イメージングに基づいたがん細胞外小胞EVsの病態機能解析
2019 - 2022 In vivo imaging system of cancer-derived exosome using a BRET reporter
2017 - 2019 Mycoplasma hyorhinis as an infectious tumor-promoting factor
2017 - 2018 マイコプラズマ感染がんにおけるシアリダーゼの機能解析
2016 - 2017 シアリダーゼ活性に着目したマイコプラズマ検出系の確立とマイコプラズマ感染がんにおけるシアリダーゼの機能解析
2016 - 2017 がんにおけるシアル酸分子スイッチの意義
2016 - 2017 腫瘍集積性希少シアル酸を利用した新規がん検出蛍光プローブの開発
Show all
Papers (23):
Ryosuke Hayasaka, Sho Tabata, Masako Hasebe, Satsuki Ikeda, Tomoya Hikita, Chitose Oneyama, Jun Yoshitake, Daisuke Onoshima, Kumiko Takahashi, Takahiro Shibata, et al. Metabolomics of small extracellular vesicles derived from isocitrate dehydrogenase 1-mutant HCT116 cells collected by semi-automated size exclusion chromatography. Frontiers in Molecular Biosciences. 2023. 9
Tomoya Hikita, Chitose Oneyama. Quantification and Imaging of Exosomes via Luciferase-Fused Exosome Marker Proteins: ExoLuc System. Bioluminescence. 2022. 281-290
Fumie Mitani, Jianyu Lin, Tatsuya Sakamoto, Ryo Uehara, Tomoya Hikita, Takuya Yoshida, Andi Setiawan, Masayoshi Arai, Chitose Oneyama. Asteltoxin inhibits extracellular vesicle production through AMPK/mTOR-mediated activation of lysosome function. Scientific Reports. 2022. 12. 1
Tomoya Hikita, Ryo Uehara, Reina E. Itoh, Fumie Mitani, Mamiko Miyata, Takuya Yoshida, Rui Yamaguchi, Chitose Oneyama. MEK/ERK-mediated oncogenic signals promote secretion of extracellular vesicles by controlling lysosome function. Cancer Science. 2022. 113. 4. 1264-1276
Shin Morioka, Hiroki Nakanishi, Toshiyoshi Yamamoto, Junya Hasegawa, Emi Tokuda, Tomoya Hikita, Tomoko Sakihara, Yuuki Kugii, Chitose Oneyama, Masakazu Yamazaki, et al. A mass spectrometric method for in-depth profiling of phosphoinositide regioisomers and their disease-associated regulation. Nature Communications. 2022. 13. 1
more...
MISC (1):
Yuuki Ishida, Chiaki Fuse, Tomoya Hikita, Kosuke Shimizu, Tomohiro Asai, Naoto Oku. Functional analysis of junctional adhesion molecule-C (JAM-C) in cancer metastasis. CLINICAL & EXPERIMENTAL METASTASIS. 2007. 24. 4. 255-255
Education (3):
2006 - 2010 大阪大学大学院 医学系研究科 予防環境学専攻
2004 - 2006 University of Shizuoka Graduate School of Pharmaceutical Sciences
2000 - 2004 University of Shizuoka School of Pharmaceutical Sciences Division of Medicinal Science
Professional career (1):
博士(医学) (大阪大学)
Work history (5):
2023/10 - 現在 University of Shizuoka School of Pharmaceutical Sciences
2019/04 - 2023/09 Aichi Cancer Center, Research Institute
2016/03 - 2019/03 Aichi Cancer Center, Research Institute
2014/06 - 2016/02 University of Shizuoka School of Pharmaceutical Sciences
2010/06 - 2014/05 Osaka University Research Institute for Microbial Diseases
Awards (4):
2017/08 - 第4回日本細胞外小胞学会 優秀奨励賞 Src enhances exosome production via interaction with ESCRT-associated protein, ALIX
2013/05 - 第40回日本マイコプラズマ学会学術集会 優秀発表賞 卵巣癌におけるマイコプラズマ感染の関与
2013/01 - 大阪大学微生物病研究所業績発表会 微研財団 優秀研究奨励賞 Involvement of mycoplasma infection in ovarian cancer progression
2010/01 - 研究奨励賞 Purvalanol A, a CDK inhibitor, effectively suppresses Src-mediated transformation by inhibiting both CDKs and c-Src
Association Membership(s) (4):
JAPANESE SOCIETY OF EXTRACELLULAR VESICLES
, JAPAN SOCIETY FOR CELL BIOLOGY
, THE JAPANESE CANCER ASSOCIATION
, 日本薬学会
※ Researcher’s information displayed in J-GLOBAL is based on the information registered in
researchmap
.
For details, see here
.
Return to Previous Page
TOP
BOTTOM